ArticleJournal of Ayurveda and integrative medicine
Tribulus terrestris L. confers protection against hypoxia induced pulmonary hypertension via regulation of HIF/ NF-κB signalling pathway.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypertension (PH) is a fatal cardiopulmonary disorder driven by hypoxia-induced vascular remodeling. The hypoxic pulmonary vasoconstriction (HPV) and increased pulmonary vascular resistance leads right ventricular failure and ultimately death. Limited therapies and poor prognosis demand novel interventions. Tribulus terrestris L., renowned for antioxidant and anti-inflammatory effects, may modulate various pathways of hypoxia induced pulmonary hypertension pathogenesis.
objectiveThis study examines potential of T. terrestris to counter hypoxia-induced PH in a rodent model via HIF-NF-κB signalling. MATERIAL AND
methodsThirty male Wistar rats were randomly undertaken, 6 rats were utilized for standardization of drug dose (T. terrestris) and remaining 24 were divided into 4 groups with 6 animals in each group as normal control, pulmonary hypertension due to intermittent hypoxia, pulmonary hypertension due to intermittent hypoxia + Tadalafil drug, pulmonary hypertension due to intermittent hypoxia + T. terrestris 250 mg/kg. Right ventricular systolic pressure (RVSP), serum levels of reactive oxygen species (ROS), nitric oxide (NO),inducible nitric oxide synthase (iNOS) and inflammatory markers-hypoxia inducible factor-1α (HIF-1α), nuclear factor-κB (NF-κB), cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in all the groups were analysed.
resultsAdministration of crude T. terrestris extract to hypoxic pulmonary hypertensive rats significantly reduced RVSP, ROS, NO, iNOS, and inflammatory markers. No significant difference in therapeutic outcomes was observed between T. terrestris and tadalafil treatment groups.
conclusionT. terrestris exhibits biochemical and hemodynamic changes associated with marked improvement in pulmonary hypertension indicating strong anti-oxidative, anti-inflammatory, and anti-angiogenic effects. This is the first study to report the protective effects of T. terrestris against hypoxic pulmonary hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.